Publication:
Design and synthesis of novel peptidomimetics for cancer immunotherapy

Simple item page
dc.contributor.authorKose, Ceyda
dc.contributor.authorUysal, Esra
dc.contributor.authorYazici, Busra
dc.contributor.authorTugay, Zeynep
dc.contributor.authorYanik, Hamdullah
dc.contributor.authorTavukcuoglu, Ece
dc.contributor.authorGulyuz, Sevgi
dc.contributor.authorAKDEMİR, ATİLLA
dc.contributor.authorESENDAĞLI, GÜNEŞ
dc.contributor.authorYilmaz, Ozgur
dc.contributor.authorAlptürk, Onur
dc.contributor.institutionauthorDİNGİŞ BİRGÜL, SERAP İPEK
dc.contributor.institutionauthorAKDEMİR, ATİLLA
dc.date.accessioned2020-11-11T22:14:08Z
dc.date.available2020-11-11T22:14:08Z
dc.date.issued2020-07-01T00:00:00Z
dc.description.abstractTumor cells benefit from some certain signals, which are referred to as -immune checkpoints-, to escape immune-mediated destruction. With that in mind, it is believed that the blockade of these points, such as programmed cell death Ligand-1 (PD-L1) and programmed cell death 1 (PD-1), can restore an adaptative immune response against tumoral cells. In this study, we have designed and synthesized some novel peptidomimetics with a 2-aminobenzathiazole scaffold, which targets the PD-1/PDL-1 pathway. In the viability assay, it was found that these compounds decreased the proliferation of peripheral blood mononuclear cells in the concentration of 10 uM. Overall, our results indicate that these novel compounds are potential checkpoint inhibitors for cancer immunotherapy.
dc.description.sponsorshipTürkiye Bilimsel Ve Teknolojik Araştırma Kurumu ( Tübitak )
dc.identifier.citationKose C., Uysal E., Yazici B., Tugay Z., Dingis-Birgul S. I. , Yanik H., Tavukcuoglu E., Gulyuz S., AKDEMİR A., ESENDAĞLI G., et al., -Design and synthesis of novel peptidomimetics for cancer immunotherapy-, ORGANIC COMMUNICATIONS, cilt.13, ss.89-102, 2020
dc.identifier.doi10.25135/acg.oc.86.20.09.1802
dc.identifier.urihttp://hdl.handle.net/20.500.12645/27379
dc.identifier.wosWOS:000575843300002
dc.titleDesign and synthesis of novel peptidomimetics for cancer immunotherapy
dc.typeArticle
dspace.entity.typePublication
local.avesis.idfcc6161f-5271-4f9a-b2bb-a14a9cd656a2
local.publication.goal03 - Sağlık ve Kaliteli Yaşam
local.publication.isinternational1
relation.isAuthorOfPublication3e5ffe11-c413-4a43-91ed-06e0978e0b21
relation.isAuthorOfPublication19bc513a-c695-4e72-ba1d-83b8d6c574c8
relation.isAuthorOfPublication.latestForDiscovery3e5ffe11-c413-4a43-91ed-06e0978e0b21
relation.isGoalOfPublication9c198c48-b603-4e2f-8366-04edcfc1224c
relation.isGoalOfPublication.latestForDiscovery9c198c48-b603-4e2f-8366-04edcfc1224c
Files
Collections
Yayınlar - Eserler